NASDAQ:IMVT
Immunovant, Inc.
Immunovant, Inc. reported net income of −$505.6M in fiscal 2026. Free cash flow was −$407.3M, and the diluted share count rose 20.4%.Summary generated from Immunovant, Inc.'s SEC filings. Latest annual report filed May 20, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−64.8%
Debt / equityn/a
Free cash flow−$407.3M
FCF marginn/a
Share count change+20.4%
Financials
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | n/a | n/a | n/a | n/a | n/a |
| Net income | −157 | −211 | −259 | −414 | −506 |
| Free cash flow | −106 | −188 | −215 | −377 | −407 |
Recent filings
- 4Insider transaction report
Oct 9, 2026 - 4Insider transaction report
Oct 9, 2026 - 8-KResults of a shareholder vote
Sep 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - DEF 14AProxy statement
Jul 22, 2026 - 10-KAnnual report for the fiscal year ended Mar 31, 2026
May 20, 2026 - 8-KResults of operations and financial condition
May 20, 2026